Capital World Investors Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Capital World Investors

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $261 Million - $274 Million	-1,800,734 Reduced 68.14%	841,900 $127 Million
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $333 Million - $584 Million	-3,999,905 Reduced 60.22%	2,642,634 $385 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $51.1 Million - $66.4 Million	464,530 Added 7.52%	6,642,539 $788 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $11.5 Million - $17.2 Million	115,628 Added 1.91%	6,178,009 $851 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $74,532 - $104,738	754 Added 0.01%	6,062,381 $842 Million
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $86.9 Million - $139 Million	1,321,691 Added 27.88%	6,061,627 $588 Million
Q1 2021 May 14, 2021	BUY	$64.07 - $91.75 $5.8 Million - $8.3 Million	90,488 Added 1.95%	4,739,936 $324 Million
Q4 2020 Feb 12, 2021	BUY	$65.07 - $98.24 $87.2 Million - $132 Million	1,340,473 Added 40.51%	4,649,448 $399 Million
Q3 2020 Nov 13, 2020	BUY	$59.04 - $77.95 $65.6 Million - $86.6 Million	1,110,384 Added 50.5%	3,308,975 $215 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $21,380 - $54,707	737 Added 0.03%	2,198,591 $161 Million
Q1 2020 May 15, 2020	BUY	$27.51 - $57.29 $15.2 Million - $31.6 Million	551,428 Added 33.49%	2,197,854 $74.8 Million
Q4 2019 Feb 18, 2020	BUY	$40.86 - $57.65 $48.1 Million - $67.8 Million	1,176,426 Added 250.3%	1,646,426 $89.6 Million
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $18.7 Million - $31.5 Million	470,000 New	470,000 $20.6 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.